A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC

Five-year survival for human papilloma virus-unrelated head and neck squamous cell carcinomas remain below 50%. We assessed the safety of administering combination hypofractionated stereotactic body radiation therapy with single-dose durvalumab (anti-PD-L1) neoadjuvantly (n = 21) (NCT03635164). The...

Descripción completa

Detalles Bibliográficos
Autores principales: Darragh, Laurel B., Knitz, Michael M., Hu, Junxiao, Clambey, Eric T., Backus, Jennifer, Dumit, Andrew, Samedi, Von, Bubak, Andrew, Greene, Casey, Waxweiler, Timothy, Mehrotra, Sanjana, Bhatia, Shilpa, Gadwa, Jacob, Bickett, Thomas, Piper, Miles, Fakhoury, Kareem, Liu, Arthur, Petit, Joshua, Bowles, Daniel, Thaker, Ashesh, Atiyeh, Kimberly, Goddard, Julie, Hoyer, Robert, Van Bokhoven, Adrie, Jordan, Kimberly, Jimeno, Antonio, D’Alessandro, Angelo, Raben, David, McDermott, Jessica D., Karam, Sana D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701140/
https://www.ncbi.nlm.nih.gov/pubmed/36434392
http://dx.doi.org/10.1038/s43018-022-00450-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701140/
https://www.ncbi.nlm.nih.gov/pubmed/36434392
http://dx.doi.org/10.1038/s43018-022-00450-6

Ejemplares similares